Strategy Inc.
Comprehensive Due Diligence on Emerging Medical Device Technologies

Strategy Inc., founded in 2000, delivers investment and market strategy due diligence for changing the standard of care medical technology. Venture capitalists and other investors, emerging entrepreneurs, and multinational medtech entities seek to determine the value of technology and answer the critical question of who is anticipated to acquire this technology, how many will they purchase, over what period, and at what price. This question requires a comprehensive evaluation of the target market and key trends driving revenues, competitive landscape, and customer profiles for the target clinical areas. founder and CEO, Nancy Patterson, and her team are proven global medical device and healthcare market research experts that combine therapy area expertise with innovative research and critical thinking.

Strategy Inc. provides strategic intelligence, not just data. Their strategic intelligence services combine in-depth primary research findings with traditional and innovative analytical tools, providing a complete view of the market and predicting the probability of successful commercialization. Additionally, Strategy Inc. has a global focus: 46 percent of business over the last ten years has been international, providing medical device consulting services to foreign entities seeking US launch of their technology.

After serving in an operational role in the sale of three emerging technologies for between $205M and $508M, at different companies, Nancy Patterson decided to leverage her capabilities by starting her own firm focused on supporting emerging companies to expedite commercialization.

Twenty years later, Nancy and her team of global researchers have aided more than 50 companies with emerging technology from formation to success at commercialization. There is also a significant business segment with a platform technology where prioritization of the indication for use with the highest probability to succeed with the maximum return is required. Each has a go-to-market plan completed to outline the optimal plan to achieve that goal.

Strategy Inc. has seen a notable shift in life sciences investment trends. Traditional venture investors are delaying investments until technology reaches a later stage, forcing emerging stage companies to seek funding from alternate sources. While Angel funders historically invested $100K ten years previously, they now could invest up to several million. Due to this shift, Angel investors now require a significantly more sophisticated due diligence.

Alternatively, for a number of investment clients, after due diligence, Strategy Inc. was able to recommend the best development stage to commit funds or to suggest that the capital would be better allocated to an alternate investment with a higher projected internal rate of return.

While clients have told us that it is as if Strategy Inc. can see the future, it is the rigorous diligence and experience that uncovers the insight that provides strategic intelligence

Investors and purchasers seek technology that affects the overall cost of care, such as prevention from hospital admittance or readmittance, in addition to the pressure to reduce treatment costs and avoid retreatments, or move treatment to less costly locations for episodes of care such as the clinic or home.

Strategy, Inc. also helps technology innovators to strategically identify market inroads. Recently, a company reached out, considering adding a fully revolutionary product category to their portfolio and sought to expand their understanding of the future therapeutic landscape, current competitors, and alternate solutions that could end up being competitors. They hired Strategy Inc. to dive deep into potential adoption, end-user needs, and treatment challenges that by solving might give them a competitive advantage. Nancy mentions, “While clients have told us that it is as if Strategy Inc. can see the future, it is the rigorous diligence and experience that uncovers the insight that provides strategic intelligence.”

Now tasked with supporting companies in the health reform era where facilities are charged with cost control, healthcare leadership is required to be more diligent than ever in formulary selection. Healthcare facilities have most all implemented Value Analysis Committees that include hospital supply chain, physicians and other healthcare providers along with administrators to approve their technology offerings through an evaluation process that compares emerging technology to existing solutions in terms of safety, efficacy, cost, outcomes and other delimiters as the final hurdle. Where once the market required a technology that addressed a significant unmet need with a safe and effective solution and regulatory approval, now we also see a request for evidence from target users and hospital systems of how the technology will lower costs and improve outcomes. Strategy Inc. considers the hurdles of the value analysis review process in their consulting and go to market strategies by performing a robust competitive positioning analysis, outlining the specific documentation that will be required by clinical area and performing a commercialization strategy on the specific technology to discuss the required components for a successful launch.

Strategy Inc. supports all strategic advisement with rigorous research. It is the key to their success. Determining the opportunities and the optimal strategies requires a comprehensive evaluation, industry experience, an in-depth understanding of the range of factors that impact success. Market analysis is an iterative process as ongoing evaluation of the business may identify additional opportunities for existing products and services, either during their growth phase or even as they mature.

Nancy has also recently contributed several chapters as an invited author in a Lippincott book on commercializing medical innovation and is also doing so for Elsevier. Insight can be garnered on her methods in these books.

Nancy is an immunologist and also has an MBA.